What is the preferred concentration of ethanolamine oleate for sclerotherapy of oral vascular anomalies? by Kato, Camila O. et al.
e468
Med Oral Patol Oral Cir Bucal. 2020 Jul 1;25 (4):e468-73. Sclerotherapy of oral vascular anomalies
Journal section: Oral Medicine and Pathology
Publication Types: Research
What is the preferred concentration of ethanolamine oleate 
for sclerotherapy of oral vascular anomalies?
Camila de Nazaré Alves de Oliveira Kato 1, Michel Campos Ribeiro 2, Mauro Henrique Nogueira Guimarães 
de Abreu 3, Soraya de Mattos Camargo Grossmann 4, Lucas Guimarães Abreu 5, Patrícia Carlos Caldeira 6, 
Ricardo Alves Mesquita 6
1 DDS, MSc, PhD student. Dept. of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Brazil
2 DDS, PhD, Oral and Maxillofacial Surgeon. Dept. of Oral and Maxillofacial Surgery, Hospital Márcio Cunha, Brazil
3 DDS, PhD, Professor. Dept. of Social and Preventive Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo 
Horizonte, MG, Brazil
4 DDS, PhD, Professor. Dept. of Oral Pathology, Pontifical Catholic University of Minas Gerais (PUC Minas), Brazil
5 DDS, PhD, Professor. Dept. of Pediatric Dentistry and Orthodontics, School of Dentistry, Universidade Federal de Minas Gerais, Brazil
6 DDS, PhD, Professor. Dept. of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Brazil
Correspondence:
Faculdade de Odontologia UFMG
Department of Oral Surgery and Pathology
Av. Antônio Carlos, 6627 sala 3204, Pampulha





Background: This study compared three different concentrations of EO (1.25%, 2.5% and 5%) for the treatment 
of oral vascular anomalies (OVAs).
Material and Methods: This was a retrospective comparative analysis of patients with OVAs treated with EO. 
Anomalies smaller than 20 mm were included. The patients were treated with 1.25% (G1), 2.5% (G2), and 5% 
(G3) and clinical data were obtained.  The number of sessions, the final volume and dose of EO were statistically 
analyzed to verify effectiveness and safety of the treatment. The different concentrations of EO were compared 
considering the number of sessions, the final volume and total dose of EO. Analysis of covariance (ANCOVA) was 
used to evaluate the influence of covariates on the outcomes. A p-value < 0.05 was considered significant.
Results: Nineteen women and 11 men with a median age of 54 years were included. The OVAs were most frequent 
in the lip (n=14) and cheek (n=9). All lesions exhibited complete clinical healing within 28 days. Patients of G3 
required fewer sessions than those of G2 (p=0.017), a lower final volume compared to the other groups (p<0.001), 
and a lower total dose than G1 (p<0.001). Patients of G1 used a lower total dose than G2 (p=0.003).
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Introduction
Sclerotherapy is an important and well-recognized treat-
ment modality for oral vascular anomalies (OVAs). Ef-
fectiveness is observed in more than 70% of the cases 
treated with sclerosing agents (1). The intralesional injec-
tion of the sclerosing agent causes irritation in the en-
dothelium followed by an inflammatory response (2,3) 
whose outcomes include fibrosis of the vessel wall or 
vein obliteration. The sclerosing agent also diffuses rap-
idly through the vessel wall and produces extravascular 
inflammation (4). Sclerotherapy has been largely used for 
the management of esophageal varix (3,5), oral heman-
gioma, vascular malformations, and varices (6-9).
Pingyangmycin, OK-432, doxycycline, sodium tetra-
decyl sulfate, polidocanol, hypertonic saline, absolute 
alcohol, bleomycin, and ethanolamine oleate (EO) are 
available for sclerotherapy of OVAs (6,7,10,11). Ethanol-
amine oleate is an unsaturated fatty acid, known for its 
lower toxic effects compared to other sclerosing agents 
(2,7,12).  However, the optimal concentration of EO 
to treat oral OVAs has not been determined. Previous 
studies have shown a good response when a concentra-
tion of 1.25%, 2.5% or 5% was used for the treatment of 
OVAs, but there were differences in the number of ses-
sions and the final volume of EO necessary to achieve 
complete resolution (2,6,7,9).
Establishing the optimal concentration of EO for sclero-
therapy of OVAs is important to provide an effective, 
safe and timeless treatment, but also to prevent or re-
duce side effects such as rash, edema, pain, bleeding, 
ulceration, or necrosis. Therefore, the aim of this pre-
liminary study was to compare the effectiveness and 
safety of sclerotherapy with EO for the treatment of 
OVAs using concentrations of 1.25%, 2.5% and 5%. 
Our hypothesis is that 5% EO is more effective and saf-
er, requiring fewer treatment sessions and a lower final 
volume and total dose.
Material and Methods
- Study design and sample
A retrospective and comparative study was carried out us-
ing the records of patients diagnosed with OVAs, who were 
treated by a single operator (R.A.M.) of the service of Oral 
and Maxillofacial Pathology Service, School of Dentistry, 
Federal University of Minas Gerais, over the past 10 years.
The diagnosis of OVAs was established based on clini-
cal criteria and on the history of the anomaly according 
to Mulliken and Glowacki (13) using the latest classi-
fication for vascular anomalies approved by the Inter-
national Society for the Study of Vascular Anomalies 
workshop (14). Functional or esthetic criteria were used 
for treatment indication.
All OVAs were treated with EO (Ethamolin™, ZEST, 
Rio de Janeiro, RJ, Brazil). Topical anesthetic gel (Ben-
zocaine 20%, Nova DFL, Rio de Janeiro, RJ, Brazil) 
was applied over the OVA for 60 seconds prior to EO in-
jection. A short insulin needle and a 1 CC syringe (BD, 
Juiz de Fora, MG, Brazil) were used for the application 
of EO. Blood was aspirated to determine whether the 
needle was inserted into the vascular lumen. After in-
jection, pressure was applied to the OVA with gauze for 
about 3 minutes to prevent reflux of EO. The patients re-
turned within 7 days for clinical follow-up. For patients 
who required more than one application to achieve com-
plete clinical resolution, an interval of 14 days between 
each application was followed.
For the current retrospective analysis, consecutively 
treated cases of OVAs were selected and only OVAs 
smaller than 20 mm were included to avoid sample 
variations. The patients were divided into three groups 
according to the concentration of EO applied. Group 1 
(G1) consisted of patients treated with EO diluted 1:4 in 
sterile water, at a final concentration of 1.25%. Group 2 
(G2) was treated with EO diluted 1:1 in distilled water, 
at a final concentration of 2.5%. Group 3 (G3) received 
undiluted EO at a final concentration of 5%. For G1 and 
G2, EO was prepared following the protocol described 
by Johann et al. (6). For G3, the drug administration 
protocol was based on Costa et al. (7).
- Variables
The following data were collected from the patient 
charts: sex, age, and skin color of the patient; clinical di-
agnosis, site, and size of the OVAs; side effects of treat-
ment (rash, edema, pain, ulceration, bleeding, and ne-
crosis); clinical healing, number of sessions performed, 
and final volume and total dose of EO used. Pain and 
edema scores were not available in the participants’ re-
cords. Therefore, the retrospective design of the study 
did not permit the retrieval and evaluation of data on 
pain and edema.
- Statistical analysis
Data analysis was carried out using the Statistical Pack-
age for the Social Sciences 17.0 (SPSS, Inc., Chicago, 
IL). The quantitative variables age, OVA size, number 
Conclusions: The concentration of 5% EO performed better than 1.25% and 2.5% for sclerotherapy of OVAs measur-
ing up to 20 mm. This preliminary result should be the preferred concentration of EO to provide an effective and safe 
treatment of OVAs.
Key words: Ethanolamine oleate, sclerotherapy, vascular malformations, hemangioma, oral mucosa.
e470
Med Oral Patol Oral Cir Bucal. 2020 Jul 1;25 (4):e468-73. Sclerotherapy of oral vascular anomalies
of sessions, final volume, and total dose were tested re-
garding normality by means of the Shapiro-Wilk test 
and a non-normal distribution was confirmed. There-
fore, two or more groups were compared using the 
Kruskal-Wallis and Mann-Whitney tests for quantita-
tive data and Fisher’s exact test for categorical variables. 
Fisher’s exact test was used to evaluate the differences 
in categorical variables. The different concentrations of 
EO were compared considering the number of sessions 
and the final volume and total dose of EO. Analysis of 
covariance (ANCOVA) was used to evaluate the influ-
ence of covariates on the outcomes. A p-value < 0.05 
was considered significant.
Results
Records of 30 patients (19 women and 11 men) were 
included in this study. The age of the patients ranged 
from 11 to 72 years (median: 54 years). Sixteen patients 
were white-skinned and 11 were non-white. Among 
the 30 OVAs, 10 were classified as hemangiomas, 10 
as vascular malformation, and 10 as varices. The most 
frequently affected site was the lip (n=14), including the 
lower (n=11) and upper lip (n=3), followed by the cheek 
(n=9), palate (n=3), tongue (n=2), gingiva (n=1), and al-
veolar mucosa (n=1). All lesions had healed completely 
within 28 days. Local pain and edema were reported by 
all patients up to 72 hours after the administration of 
EO. As local pain and edema were not quantified, they 
were not considered in the statistical analysis. No other 
side effects were reported. Table 1 shows the compari-
son of participants’ age, clinical diagnosis of OVAs, and 
OVA size.
There was no difference in sex among groups (Fisher’s 
exact test, p=0.51). The groups differed in terms of age 
(Kruskal-Wallis test, p=0.043) and clinical diagnosis 
(Fishers exact test, p=0.004). Patients of G1 were signif-
icantly younger than those of G3 (Mann-Whitney test, 
p=0.016). Significant differences in the clinical diagno-
sis were also observed between G1 and G3 (Fisher’s ex-
act test, p=0.001), with a predominance of hemangioma 
cases in G1 (n=7) and of varices in G3 (n=6). There was 
no significant difference in OVA size between groups 
(Kruskal-Wallis test, p=0.15).
The Kruskal-Wallis test showed significant differenc-
es among groups for the variables number of sessions 
(p=0.047), final volume (p<0.001), and total EO dose 
(p<0.001) (Table 2). Comparisons between groups by the 
Mann-Whitney test revealed a significant difference in 
the number of sessions between G3 and G2 (p=0.017). 
The final volume of EO was lower in G3 compared to G1 
(p<0.001) and G2 (p<0.001). The total EO dose was high-
er in G2 than in G1 (p=0.003) and G3 (p<0.001). After 
ANCOVA, the differences in the total dose (p=0.036) be-
tween G1 and G2 and in final volume between G1 and G3 
(p=0.016) remained statistically significant, regardless of 
participant age, clinical diagnosis, and OVA size (Table 
3). ANCOVA was not necessary for the comparison be-
tween G2 and G3 because these two groups were similar 
in terms of participant age (p=0.478), clinical diagnosis 
(p=0.25), and OVA size (p=0.87).
Table 1: . Clinical data of the patients treated with ethanolamine oleate for oral vascular anomalies.









G1 x G2 G2 x G3 G1 x G3
Patients (n) 10 10 10





a 0.089 b 0.478 b 0.016 b
Clinical 
diagnosis
Hemangioma 7 3 0 0.004 c 0.073 c 0.250 c 0.001 c
Venous malformation 3 3 4
Varices 0 4 6






0.150 a 0.104 b 0.870 b 0.090 b
















G1 x G2 G2 x G3 G1 x G3
Number of sessions (n) 1 (1-4) 2 (1-3) 1 (1-2) 0.047 0.646 0.017 0.141
Final volume (mL) 1 (1-4) 2 (1-3) 0.3 (0.1-0.4) <0.001 0.646 <0.001 <0.001




(0.005-0.0200) <0.001 0.003 <0.001 0.129
a Kruskal-Wallis test significant p<0.05; b Mann-Whitney test corrected by Bonferroni test significant p<0.016; Groups:  G1– 1.25%, G2– 2.5% 
and G3 – 5% of ethanolamine oleate.
Table 2: Comparison of the different concentrations of ethanolamine oleate to treat oral vascular anomalies.
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Discussion
This preliminary study compared three different EO 
concentrations for the treatment of OVAs. The hypoth-
esis that 5% EO (G3) requires a lower final volume and 
total dose and fewer sessions was confirmed. Using 
5% EO, only one or two sessions were necessary for 
complete clinical resolution of the lesion, whereas at 
concentrations of 1.25% and 2.5%, the number of ses-
sions ranged from one to four. A reduction in the num-
ber of sessions associated with the use of 5% EO was 
also observed by Costa et al. (7) and Fernandes et al. 
(9). The use of 1.25% and 2.5% EO may require one to 
10 sessions for the complete clinical resolution of OVAs 
(2,6,15).
A recent systematic review on sclerosing agents has 
shown that pingyangmycin, absolute ethanol, OK-432, 
EO, bleomycin, polidocanol, doxycycline, and sodium 
tetradecyl sulfate appear to be effective, although po-
tential complications associated with each agent should 
be considered when selecting a drug (1). Pain/burning 
upon injection, temporary scars, psychological issues, 
rash, ulcerations, bleeding, and the risk of local necro-
sis are complications of sclerotherapy (1,8,16). For EO, 
these adverse effects are mainly related to the dose ap-
plied, and a total dose of 0.4 ml/kg has been consid-
ered the maximum safe dosage of EO (13,17). The size 
of OVAs is also an important factor for sclerotherapy 
mainly because of the possible toxic effect of EO. The 
absence of the other side effects was expected because 
of the pre-defined limitation of OVA size, smaller than 
20 mm, which required a lower dose of EO ranging 
from 0.005 g to 0.075 g, and even lower dose when EO 
was used at a concentration of 5%. Sclerotherapy of 
anomalies larger than 20 mm is likely to result in more 
adverse effects (52.9%) such as superficial necrosis, and 
thus requires careful monitoring (18).
There was no difference in sex among the participants, 
but patients of G1 were younger than those of G3. Pa-
tient age may have influenced the results, as there was 
a difference between groups. A reduced inflammatory 
response is observed in the elderly due to the physiolog-
ical aging process (19-21). The OVAs were larger in G1 
than in G2 and G3. After ANCOVA, the differences in 
the total dose between G1 and G2 and in the final vol-
ume between G1 and G3 were attenuated, but remained 
significant regardless of the participants’ age, clinical 
diagnosis of OVA, and OVA size. The size of the le-
sion and the clinical diagnosis are important variables 
for evaluation of the clinical response. Larger lesions 
may require more sessions and consequently a higher 
volume and final dose.
Numerous techniques such as surgery, embolization, 
laser therapy, systemic corticosteroids, cryotherapy, in-
terferon α and radiation therapy have been recognized 
as treatments of OVAs (8,22-25). Deciding upon which 
technique will offer the best results depends on the size, 
location and hemodynamics of the lesion, the degree of 
invasion into anatomic structures, and the age of pa-
tients (8,26). The sclerosis technique consists of direct 
percutaneous puncture and is an easy, simple, fast and 
low-cost technique that can be carried out in an outpa-
tient setting with low morbidity and well tolerated by 
the affected individual. The clinician’s experience also 
contributes to successful sclerotherapy (9). For several 
sclerosing agents, sclerotherapy is effective in more 
than 70% of cases of cervicofacial anomalies, while EO 
has a success rate higher than 88% (1). In our study, the 
inclusion of OVA cases smaller than 20 mm may ex-
plain the success rate in all cases of the present sample 
treated with three different concentrations of EO.
With respect to the technique, we used a topical anes-
thetic prior to EO injection. In addition, distilled water 
was used to dilute EO, as previously reported (2,15). 
However, other studies have recommended the intravas-
cular application of EO diluted in 2% lidocaine and epi-
nephrine (1:100,000), as well as anesthetic infiltration 
with vasoconstrictor around the lesion (8,9). The objec-
tive of topical application of the anesthetic is to avoid 
the possible interaction between both drugs. Moreover, 
the use of infiltrative anesthesia may hinder visualiza-
tion of the lesion and interfere with the technique of EO 
injection.
This study has some limitations. The retrospective 
study design with data extraction from medical records 
has disadvantages, although the treatment was per-
formed by the same service. The pain and edema scores 
of individuals treated with the three different concen-
trations of EO could have been relevant information for 
clinical practice. However, information on pain or ede-
ma scores was not available in the participants’ records. 
Therefore, the retrospective design of the study did not 
permit assessment of these data. Another limitation is 
the heterogeneity among groups with respect to partici-
pant age and clinical diagnosis. Despite the similarity 
between G2 and G3, there was a difference in age and 
clinical diagnosis between G1 and G2 and between G1 
G1 x G3 Final volume F statistics p-value
Age 0.094 0.764
Clinical diagnosis 0.914 0.423
Size 3.878 0.069
Concentration (G1 x G3) 7.558 0.016
G1 x G2 Total dose
Age 0.012 0.915
Clinical diagnosis 0.501 0.616
Size 1.589 0.228
Concentration (G1 x G2) 5.346 0.036
Groups:  G1– 1.25%, G2– 2.5% and G3 – 5% of ethanolamine oleate.
Table 3: Analysis of covariance (ANCOVA) for final volume and 
total dose of ethanolamine oleate to treat oral vascular anomalies.
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and G3. We therefore applied ANCOVA to assess dif-
ferences in the total dose between G1 and G2 and in the 
final volume between G1 and G3 considering age, clini-
cal diagnosis and size of the lesion as confounders. The 
difference in final volume between G1 and G3 and in 
the total dose between G1 and G2 remained significant, 
regardless of the influence of confounders. Randomized 
clinical trials are needed in the future to allow a more 
appropriate evaluation of treatments.
Conclusions
Despite the cited limitations, our preliminary results 
demonstrate that 5% EO for the treatment of OVAs 
smaller than 20 mm resulted in a lower final volume, 
lower total dose and a tendency towards fewer sessions 
than 1.25% and 2.5%. This should therefore be the pre-
ferred concentration of EO to treat OVAs of 20 mm or 
less. Further studies, especially randomized clinical tri-
als, are warranted to establish an assertive protocol for 
OVA sclerotherapy. However, these preliminary results 
may help clinicians choose the EO concentration for the 
treatment of OVAs.
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